Brief: FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation
05/11/2025 18:31
Nov 5 (Reuters) - FDA: FDA: APPROVED LINZESS (LINACLOTIDE) CAPSULES FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION FDA: LINZESS RECOMMENDED DOSAGE FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IBS-C IS 145 MCG ORALLY ONCE DAILY Further company coverage: IRWD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation